First Affirmative Financial Network Grows Position in Boston Scientific Co. (NYSE:BSX)

First Affirmative Financial Network grew its stake in shares of Boston Scientific Co. (NYSE:BSX) by 15.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,054 shares of the medical equipment provider’s stock after buying an additional 660 shares during the period. First Affirmative Financial Network’s holdings in Boston Scientific were worth $424,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in BSX. FIL Ltd grew its position in shares of Boston Scientific by 1.4% in the fourth quarter. FIL Ltd now owns 5,944,746 shares of the medical equipment provider’s stock valued at $343,666,000 after purchasing an additional 80,534 shares during the period. Voisard Asset Management Group Inc. purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $46,000. Raleigh Capital Management Inc. boosted its holdings in Boston Scientific by 10.1% in the fourth quarter. Raleigh Capital Management Inc. now owns 3,479 shares of the medical equipment provider’s stock valued at $201,000 after acquiring an additional 318 shares during the last quarter. Sierra Summit Advisors LLC acquired a new position in Boston Scientific in the fourth quarter valued at $8,038,000. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in Boston Scientific by 9.8% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 514,973 shares of the medical equipment provider’s stock valued at $29,770,000 after acquiring an additional 45,808 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the sale, the executive vice president now directly owns 160,467 shares in the company, valued at $13,639,695. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the sale, the executive vice president now owns 160,467 shares in the company, valued at approximately $13,639,695. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total value of $570,511.10. Following the sale, the executive vice president now owns 37,468 shares of the company’s stock, valued at $3,061,135.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 316,253 shares of company stock worth $26,714,298 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $87.10 on Friday. The company has a current ratio of 1.61, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44. The stock has a 50 day simple moving average of $81.21 and a 200-day simple moving average of $76.44. The company has a market cap of $128.27 billion, a PE ratio of 70.81, a P/E/G ratio of 2.87 and a beta of 0.80. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $87.28.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.04. The business had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The business’s revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.53 earnings per share. On average, equities research analysts forecast that Boston Scientific Co. will post 2.4 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. TD Cowen lifted their target price on Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. Barclays lifted their target price on Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Thursday, August 22nd. BTIG Research lifted their target price on Boston Scientific from $80.00 to $84.00 and gave the company a “buy” rating in a report on Monday, July 15th. Citigroup boosted their price objective on Boston Scientific from $90.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, JPMorgan Chase & Co. boosted their price objective on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, July 25th. Three investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.